A prospective “oversizing” strategy of the Edwards SAPIEN bioprosthesis: Results and impact on aortic regurgitation  by Samim, Mariam et al.
Acquired Cardiovascular Disease Samim et al
A
C
DA prospective ‘‘oversizing’’ strategy of the Edwards SAPIEN
bioprosthesis: Results and impact on aortic regurgitationMariam Samim, BSc,a Pieter R. Stella, MD, PhD,a Pierfrancesco Agostoni, MD, PhD,a
Jolanda Kluin, MD, PhD,b Faiz Ramjankhan, MD,b Gertjan Sieswerda, MD, PhD,a
Ricardo Budde, MD, PhD,a Marijke van der Linden, RN,a Francis Juthier, MD,c Carlo Banfi, MD,c
Christopher Hurt, MD,c Morsal Samim, BSc,a Marieke Hillaert, MD,a Lex van Herwerden, MD, PhD,b
Michel E. Bertrand, MD,c Pieter A. M. Doevendans, MD, PhD,a and Eric Van Belle, MD, PhDcFrom th
ter, U
Lille,
Disclosu
thors
Receive
public
Address
Franc
(E-ma
0022-52
Copyrig
doi:10.1
398Objective:Moderate to severe aortic regurgitation is occurring in 20% to 30% of cases after transcatheter aortic
valve implantation.
Methods: The purpose of the study was to investigate the impact of a prospective policy of ‘‘oversizing’’ the
Edwards SAPIEN bioprosthesis (Edwards Lifesciences LLC, Irvine, Calif) relative to the diameter of the aortic
annulus on the rate and severity of aortic regurgitation in 28 consecutive patients initially considered eligible for
transcatheter aortic valve implantation on the basis of angiography, multislice computed tomography, and trans-
thoracic echocardiography. This policy included the systematic use of transesophageal echocardiography to ex-
clude borderline patients and the modification of the procedure to use the larger device possible. The results were
studied on an individual patient basis.
Results: Because 6 of 28 patients (21%) had an annulus diameter greater than 24 mm by transesophageal echo-
cardiography, 22 patients underwent implantation of the Edwards SAPIEN prosthesis. In 6 of 22 patients, the
procedure was adapted to follow our ‘‘oversizing’’ policy. As a result, the ‘‘prosthesis/annulus cover index’’
was 12.4%  4.3%. The procedure was successful in 21 of 22 patients (95%), and 18 patients were available
for echocardiography at 1 month. Although a moderate to severe aortic regurgitation was observed pretreatment
in 4 of 18 patients (22%), it was no longer the case at 1 month (0/18, 0%; P¼ .03). The improvement was sec-
ondary to a disappearance of the aortic regurgitation in all 7 patients with a significant aortic regurgitation at
pretreatment, whereas the new aortic regurgitations appearing in 5 of the 11 patients with no aortic regurgitation
at pretreatment were only mild aortic regurgitations.
Conclusions: In patients with a successful implantation of an Edwards SAPIEN valve, a simple ‘‘oversizing’’
policy based on a systematic use of transesophageal echocardiography and modification of the procedure may
prevent the occurrence ofmoderate and severe aortic regurgitations. (J ThoracCardiovasc Surg 2013;145:398-405)Transcatheter aortic valve implantation (TAVI) is a develop-
ing technique to treat patients with aortic stenosis.1,2
Because questions remain concerning safety and
durability, its use currently is limited to patients
contraindicated or at very high risk for conventional aortic
valve replacement.
After TAVI, a moderate to severe paravalvular aortic re-
gurgitation (AR) can occur in approximately 20% to 30%
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The Journal of Thoracic and Cardiovascular Surgconsidered as acceptable in the elderly population, it is
a limitation to a broader use of this technique.
Implantation of an undersized prosthesis has been
proposed as a major cause of this issue.3,57 Although it is
usually recommended to ‘‘oversize’’ the implantation of
the Edwards SAPIEN bioprosthesis (Edwards Lifesciences
LLC, Irvine, Calif) relative to the annulus diameter as
measured by transesophageal echocardiography (TEE) by
2 to 4 mm, this rule is not strictly applied, particularly in
patients with a large annulus or borderline vascular
accesses.3 To date, the benefit of a strict ‘‘oversizing’’ policy
on the severity of AR has never been investigated.
When starting our TAVI program with the Edwards SA-
PIEN bioprosthesis, we decided to implement a prospective
policy of systematic ‘‘oversizing’’ the bioprosthesis relative
to the diameter of the aortic annulus and to test its impact on
the rate and severity of AR. This issue was studied bymeans
of serial 2-dimensional transthoracic echocardiography
(TTE) Doppler cardiography performed before the proce-
dure, before discharge, and at 1 month.ery c February 2013
Abbreviations and Acronyms
AR ¼ aortic regurgitation
AVI ¼ aortic valve implantation
LV ¼ left ventricular
TA ¼ transapical
TAVI ¼ transcatheter aortic valve implantation
TEE ¼ transesophageal echocardiography
TF ¼ transfemoral
TTE ¼ transthoracic echocardiography
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Patient Population and Selection
Patients with severe aortic stenosis considered to be at high or prohibi-
tive surgical risk were considered to undergo TAVI with the Edwards SA-
PIEN valve at University Medical Center, Utrecht, The Netherlands.
Consensus was achieved between cardiologists and cardiac surgeons re-
garding the surgical risk, and all patients provided informed written
consent.
To determine the initial eligibility for TAVI and to choose between the
transfemoral (TF) aortic valve implantation (AVI) or the transapical (TA)-
AVI approach, all patients underwent coronary angiography, aortobife-
moral angiography, multislice computed tomography, and TTE. Potential
candidates for TAVI demonstrated symptomatic degenerative aortic steno-
sis with at least New York Heart Association class 2 symptoms and an aor-
tic valve area of 1.0 cm2 or mean gradient greater than 40 mm Hg or peak
gradient greater than 80 mm Hg. All candidates were contraindicated for
conventional surgery or considered a high surgical risk with an operative
mortality risk of greater than 20% as assessed by at least 2 cardiovascular
surgeons and 2 cardiologists.8
Patients were excluded from TAVI if they had at least 1 of the following:
(1) aortic annulus diameter less than 16 mm or greater than 24 mm by TTE;
(2) congenital unicuspid or bicuspid valve; (3) noncalcified valve; (4) un-
treated clinically significant proximal coronary artery disease; (5) severe
left ventricular (LV) dysfunction less than 20%; or (6) hemodynamic insta-
bility requiring inotropic support.
All patients were considered as potential candidates for TF-AVI unless
they had at least 1 of the following: (1) mobile aortic arch atheroma greater
than 5mm or (2) iliofemoral dimensions, morphology, or calcifications that
would preclude insertion of a 22F sheath or 24F introducer sheath based on
a detailed assessment of aortobifemoral angiography and multislice com-
puted tomography, in which case they were considered for TA-AVI.
On the basis of this initial selection process, 28 patients were considered
potential candidates. All patients underwent TEE before the final planning
of the procedure. As part of our ‘‘oversizing’’ policy (see below), thosewith
an annulus diameter greater than 24 mm by TEE were further excluded and
did not undergo the procedure.
Choice of Bioprosthesis Size and ‘‘Oversizing’’ Policy
The Edwards SAPIEN transcatheter heart valve is a catheter-delivered
heart valve that is composed of a stainless-steel balloon-expandable stent,
with an integrated trileaflet tissue valve and a polyethylene terephthalate
fabric cuff. The valve tissue is made from 3 equal sections of bovine peri-
cardium treated with a proprietary tissue treatment. During the time of the
study, the bioprosthesis was available in 2 sizes (23 and 26 mm) and could
be delivered through the TF or TA approach.
Our ‘‘oversizing’’ policy for the implantation of the Edwards SAPIEN
bioprosthesis was defined as follows: (1) All patients with an aortic annu-
lus greater than 24 mm by TEE during the final step of the screening wereThe Journal of Thoracic and Castrictly excluded (see above); (2) a 26-mm prosthesis was implanted in all
patients with an annulus greater than 21 mm, and the TA approach was
used every time it was needed; and (3) in patients with an annulus 21
mm or less, a 26-mm prosthesis was also implanted every time the balloon
predilatation with a 23-mm balloon associated with contrast angiography
at maximum balloon inflation demonstrated a significant aortic
regurgitation.
To appreciate the degree of ‘‘oversizing,’’ the ‘‘prosthesis/annulus cover
index’’ expressed as 1003 ([prosthesis diameter – TTE annulus diameter]/
prosthesis diameter) was used, as suggested by Detaint and colleagues.3
Transcatheter Aortic Valve Implantation
The prosthetic stented valve was mechanically crimped on a balloon
catheter immediately before implantation. The Retroflex delivery system
(Edwards Lifesciences) was used for device implantation.6,9,10
TF and TA-AVI were performed under general anesthesia in the cathe-
terization laboratory as previously described.6,9,10 TEE was used for all
procedures. Patients were premedicated with aspirin and antibiotics.
Heparin was used to maintain an activated clotting time greater than 300
seconds. The activated clotting time was reversed with protamine at the
end of the procedure.
For TF-AVI, our technique was similar to that in previously described
reports.6,9 A surgical cut-down of the femoral arty was performed, and
a 14F sheath was initially placed. A temporary transvenous electrode
was introduced into the right ventricle. Balloon aortic valvuloplasty with
a 20- or 23-mm balloon was performed. The balloon-mounted valve was
positioned using angiographic techniques and echocardiographic guid-
ance, and subsequently deployed under rapid pacing (180–220 beats/
min). Exit peripheral angiography was performed to ensure no extravasa-
tion of contrast before removal of femoral sheath. The sheath was removed
and closed surgically in the operating room by a surgeon immediately
postprocedure.
The TA-AVI procedure was performed as previously described.10 For
the purpose of rapid ventricular pacing, 2 unipolar epicardial pacer wires
were secured and tested with a high-output epicardial pacing system to en-
sure ventricular capture at rates of 180 to 220 beats/min.
Procedural success was defined as the implantation of a functional pros-
thetic valvewithin the aortic annulus at the end of the procedurewithout in-
laboratory mortality. Patients received aspirin (81 mg/d) and clopidogrel
(75 mg/d) indefinitely. Warfarin was substituted for clopidogrel in patients
with atrial fibrillation.
Echocardiography Follow-up
TEE was the final step of the screening process and was performed dur-
ing the procedure in all patients. TTE was performed during the screening
process, pretreatment (last echocardiography study before TAVI), post-
treatment (at discharge), and postdischarge (first outpatient clinic visit) us-
ing a Philips 5500 or ie33 system (Philips, Eindhoven, The Netherlands).
Complete echocardiographic studies were performed for each patient in
a standard fashion. Standard parameters were recorded.11 By using the par-
asternal long-axis view and M-mode or 2-dimensional echocardiography,
LV diameters, function, and outflow track diameter were obtained.
To assess the severity of aortic stenosis peak aortic velocity, peak instan-
taneous gradient, mean transaortic gradient, and velocity-time integral
were measured. Aortic valve area was estimated using the continuity equa-
tion approach.12
The color-flow Doppler signal was used to assess aortic regurgitation.
According to the European Society of Cardiology guidelines and American
Society of Echocardiography recommendations, valvular insufficiency was
graded in 5 groups as none (¼0), trivial (¼1), mild (¼2), moderate (¼3), or
severe (¼4).13,14 A valvular insufficiency of 2 or greater was considered
significant. More specifically, regurgitation was assessed by visual
inspection and by using color-flow mapping of the regurgitation jet as de-
scribed by Zoghbi and colleagues14 and Helmcke and colleagues.15 Ardiovascular Surgery c Volume 145, Number 2 399
TABLE 1. Clinical and echocardiography characteristics of the 28 patients
Total
Excluded
N ¼ 6
Included
N ¼ 22 P Transfemoral Transapical P
Age (y) 80  8 80  9 79  7 .71 78  7 80  8 .61
Male, n (%) 17 (61) 6 (100) 11 (50) .02 4 (40) 7 (58) .66
BMI (kg/m2) 27  6 28  4 26  5 .04 26  7 26  4 .85
Hypertension, n (%) 21 (75) 5 (83) 16 (73) .58 7 (70) 9 (75) .80
Atrial fibrillation, n (%) 12 (43) 2 (33) 10 (45) .59 5 (50) 5 (42) .70
Diabetes, n (%) 5 (18) 1 (17) 4 (18) .93 2 (20) 2 (17) .84
Coronary artery disease, n (%) 16 (57) 3 (50) 13 (59) .69 3 (30) 10 (83) .02
Prior myocardial infarction, n (%) 8 (29) 1 (17) 7 (32) .45 2 (20) 5 (42) .38
Percutaneous coronary intervention, n (%) 11 (39) 2 (33) 9 (41) .73 2 (20) 7 (58) .06
Coronary artery bypass, n (%) 7 (25) 1 (17) 6 (27) .58 2 (20) 4 (33) .64
Cerebrovascular events, n (%) 8 (29) 1 (17) 7 (32) .45 3 (30) 4 (33) .87
Peripheral vascular disease, n (%) 3 (11) 1 (17) 2 (9) .61 0 (0) 2 (17) .48
Renal disease, n (%) 6 (21) 1 (17) 5 (23) .74 2 (20) 3 (25) .78
COPD, n (%) 8 (29) 2 (33) 6 (27) .77 3 (30) 3 (25) .79
NYHA class, n (%)
I 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
II 3 (11) 1 (17) 2 (9) .74 1 (10) 1 (8) .40
III 22 (78) 4 (66) 18 (82) 9 (90) 9 (75)
IV 3 (11) 1 (17) 2 (9) 0 (0) 2 (17)
Logistic euroSCORE 21.8  13.3 23.2  16.3 21.3  14.1 .81 18.1  15.5 24.1  12.8 .33
LVEF<35%, n (%) 6 (21) 1 (17) 5 (23) .74 2 (20) 3 (25) .78
LV end-diastolic diameter (mm) 46.2  4.5 47.5  5.3 45.7  5.3 .43 45.3  6.1 46.2  4.8 .71
Mean aortic gradient (mm Hg) 42  15 44  15 41  16 .55 40  16 41  17 .88
Peak aortic gradient (mm Hg) 71  24 73  21 70  26 .65 70  27 71  26 .95
Aortic valve area (cm2) 0.72  0.19 0.69  0.14 0.73  0.19 .25 0.73  0.17 0.73  0.21 .96
Annulus diameter by TTE (mm) 21.8  1.2 22.5  1.1 21.6  1.3 .10 21.5  1.4 21.6  1.5 .91
Annulus diameter by TEE (mm) 22.6  1.4 24.9  0.4 22.0  1.3 .01 22.1  1.3 22.0  1.3 .86
No significant AR, n (%) 16 (57) 3 (50) 13 (59) .69 5 (50) 8 (67) .72
Significant AR, n (%) 12 (43) 3 (50) 9 (41) 5 (50) 4 (33)
Aortic regurgitation grade (0–4) 1.55  0.95 1.33  0.82 1.55  1.01 .35 1.80  1.40 1.33  0.49 .29
BMI, Body mass index; COPD, chronic obstructive pulmonary disorder; NYHA, New York Heart Association; euroSCORE, European System for Cardiac Operative Risk Eval-
uation; LVEF, left ventricular ejection fraction; LV, left ventricular; TTE, transthoracic echocardiography; AR, aortic regurgitation. Data are mean standard deviation otherwise
stated.
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clinical status, graded AR.
Statistical Analysis
Continuous variables were presented as mean  standard deviation.
Discrete variables were presented as absolute numbers and percentages.
For comparison between categoric variables, a chi-square test was used.
A 1-way analysis of variance test was used for comparison between contin-
uous variables. A 1-way repeated-measures Friedman test with post hoc
analysis was used to evaluate changes over time. Analyses were performed
using SPSS 18.0 (SPSS Inc, Chicago, Ill).RESULTS
Characteristics of the Study Population and
Procedure
The baseline clinical and echocardiography characteris-
tics of the study population are shown in Table 1. On the ba-
sis of the measurement of the annulus diameter by TTE
(<24 mm), 28 patients were initially considered eligible
for implantation. On the basis of the subsequent400 The Journal of Thoracic and Cardiovascular Surgmeasurement of the annulus diameter by TEE (>24 mm)
during the final step of the screening process, 6 of 28 pa-
tients (21%) were excluded. By definition and comparison
with the remaining 22 patients, the annulus diameter of
these 6 patients as measured by TEE was larger (P ¼ .01,
Table 1). This difference was not detectable by TTE
(P ¼ .10, Table 1). The 6 excluded patients were male
(100%) and had a higher body mass index (P ¼ .04) than
the remaining 22 patients (Table 1).
The medical decision in the 6 patients in whom the TAVI
procedure was not performed was as follows: One patient
underwent conventional aortic replacement and was alive
at 12 months follow-up; 1 patient was eligible for the im-
plantation of a 29-mmCoreValve (Medtronic Inc, Minneap-
olis, Minn) (the procedure was successful, and the patient
died at 7 months follow-up); the last 4 patients underwent
conservative medical management (2 patients died within
12 months and 2 patients remained alive at 1 year under
conservative treatment; 1 of the last 2 patients recentlyery c February 2013
TABLE 2. Procedural characteristics and 30-day outcome
Total
N ¼ 22
Transfemoral
N ¼ 10
Transapical
N ¼ 12 P
Annulus diameter
(mm), mean  SD
22.0  1.3 22.1  1.3 22.0  1.3 .86
Aortic valve area (cm2),
mean  SD
0.73  0.19 0.73  0.17 0.73  0.21 .95
Prosthesis diameter,
n (%)
23 mm 6 (27) 3 (30) 3 (25) .79
26 mm 16 (73) 7 (70) 9 (75)
Cover index,%,
mean  SD
12.4  4.3 11.8  5.5 12.8  3.2 .58
Successful valvuloplasty,
n (%)
22 (100) 10 (100) 12 (100) 1
Successful valve
deployment, n (%)
21 (95) 10 (100) 11 (92) .35
Intraprocedural death,
n (%)
0 (0) 0 (0) 0 (0) 1
30-d outcome
Myocardial infarction 1 (4) 0 (0) 1 (8) .35
Stroke, n (%) 0 (0) 0 (0) 0 (0) 1
Permanent pacemaker 1 (4) 0 (0) 1 (8) .35
Mortality, n (%) 4 (18) 1 (10) 3 (25) .35
SD, Standard deviation. Cover index as 100 3 (prosthesis diameter – annulus diam-
eter by TEE/prosthesis diameter).
FIGURE 1. Patient flow chart. TEE, Transesophageal echocardiography;
TTE, transthoracic echocardiography.
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bioprosthesis).
Among the 22 remaining patients, 12 underwent TA-AVI
and 10 underwent TF-AVI. Patients who underwent TA-
AVI rather than TF-AVI were more likely to have a history
of coronary artery disease (P ¼ .02). The other characteris-
tics were not different between the groups.
The relatively low mean annulus diameter (22.0  1.3
mm, Tables 1 and 2) of the population in whom the
procedure was performed reflects the exclusion of all
patients with an annulus greater than 24 mm by TEE as
part of our ‘‘oversizing’’ policy. Furthermore, in 6 of 22
patients the procedure was modified: In 3 patients with an
annulus greater than 21 mm and suitable for a 22F but not
for a 24F iliofemoral sheath, a TA approach was used. In
3 other patients with an annulus 21 or less by TTE, a 26-
mm rather than a 23-mm prosthesis was implanted on the
basis of the results of balloon predilatation associated
with angiography. As a result, the ‘‘prosthesis/annulus
cover index’’ was 12.4% 4.3%. Using a 23-mm prosthe-
sis in the 6 cases mentioned above would have led to a sig-
nificantly lower ‘‘cover index’’ (9.9%  3.6%, P ¼ .02).
The procedure was successful in 21 of 22 patients (95%,
Table 2). The patient with unsuccessful valve implant was
an 85-year-old man with a history of myocardial infarction,
bypass surgery, and peripheral vascular disease. The tech-
nical failure was related to the inability to perform appro-
priate hemostasis at the level of the purse at the apex of theThe Journal of Thoracic and Caleft ventricle related to pericardial adherences. The proce-
dure was aborted and converted to open surgery for con-
ventional valve replacement. Although the surgical
intervention was successful, the patient died of multiorgan
failure on day 11. Another patient died of right ventricular
failure secondary to an inferior myocardial infarction in
hospital on day 3 from. These 2 in-hospital deaths were ob-
served among the 12 patients who underwent a TA-AVI
procedure. No procedural failure and no hospital death
were observed in the 10 patients who underwent a TF-AVI
procedure. One patient who underwent TA-AVI required
a permanent pacemaker implantation before discharge.
No rupture of the aortic annulus was observed. No case
of severe AR was observed immediately after balloon
valvuloplasty by TEE. After implantation of the biopros-
thesis, fluoroscopy did not show any distortion of the
edges of the stent supporting the valve. Likewise, TEE per-
formed in short axis showed that the circularity of the stent
was preserved. Overall, 20 patients (91%) underwent a suc-
cessful procedure and were discharged alive from the
hospital.
Within the first 30 days, 2 additional patients died of pul-
monary infection in the TA-AVI group (1) and sudden death
(1) in the TF-AVI group. No stroke was observed. Eighteenrdiovascular Surgery c Volume 145, Number 2 401
TABLE 3. Echocardiography findings during follow-up (N ¼ 18)
Pretreatment
Post-
treatment Postdischarge P
LVEF<35%, n (%) 3 (23) 2 (15) 3 (17) .57
TF 1 (11) 1 (11) 1 (11)
TA 2 (22) 1 (11) 2 (25)
LV end-diastolic
diameter (mm)
45.7  5.9 45.2  5.5 44.7  5.3 .03
TF 45.0  6.3 44.7  5.5 44.3  4.9
TA 46.4  5.5 45.8  5.6 45.1  5.7
Mean aortic gradient
(mm Hg)
42  17 9  4 8  3 .0001
TF 41  17 12  4 9  3
TA 44  18 7  2 7  2
Peak aortic gradient
(mm Hg)
73  26 17  6 15  6 .0001
TF 73  28 21  6 17  8
TA 75  27 13  4 13  4
Aortic valve area
(cm2)
0.72  0.21 1.87  0.45 1.81  0.31 .0001
TF 0.73  0.18 1.87  0.50 1.86  0.34
TA 0.71  0.24 1.88  0.43 1.75  0.30
Aortic regurgitation
grade (0–4)
1.56  1.10 1.17  0.71 0.89  0.83* .03
TF 1.78  1.48 1.22  0.67 1.11  0.78
TA 1.33  0.50 1.11  0.78 0.67  0.87
All parameters are mean  standard deviation, otherwise stated. P reflects the differ-
ence among the 3 time points by 1-way repeated measures Friedman test. LVEF, Left
ventricular ejection fraction; TF, transfemoral; TA, transapical; LV, left ventricular.
*P<.05 compared with ‘‘pretreatment’’ by post hoc analysis of the Friedman test.
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charge (Figure 1).
Echocardiography Analysis
The echocardiography findings of the 18 patients with an
echocardiography at 1 month are summarized in Table 3.
There was a statistically significant decrease in the peak
(pretreatment 73  26 mm Hg vs post-treatment 17  6
mm Hg vs 1 month 15  6 mm Hg, P<.0001) and mean
gradient (pretreatment 42  16 mm Hg vs post-treatment
9  4 mm Hg vs 1 month 8  3 mm Hg, P<.0001) after
Edwards implantation, which was associated with an in-
crease in the aortic valve area (pretreatment 0.72  0.21
cm2 vs post-treatment 1.87  0.45 cm2 vs 1 month 1.81
 .32 cm2, P<.0001). Ventricular function did not change
significantly during follow-up. No difference was observed
between patients treated through the TF or TA approach.
Before treatment, a significant AR was observed in 9 of
22 patients (41%, Table 1). AR was mild, moderate, and se-
vere in 5 patients (23%), 3 patients (13%), and 1 patient
(5%), respectively. The degree of AR before and 1 month
after Edwards SAPIEN valve implantation in the 18 patients
with echocardiography follow-up is shown in Table 3 and
Figure 2,A. Although amoderate to severeARwas observed
in 4 of 18 patients (22%) before treatment, it was no longer402 The Journal of Thoracic and Cardiovascular Surgthe case at 1 month (P¼ .03, Figure 2, A). The improvement
was secondary to a disappearance of the AR in all 7 patients
with a significant AR before treatment, whereas the new
ARs appearing in 5 of the 11 patients with no AR at pretreat-
ment were only mild (Table 4; Figure 2, B).DISCUSSION
The present study is the first to show that in patients re-
ferred for TAVI for aortic stenosis, a simple prospective
strategy of ‘‘oversizing’’ the implantation of the Edwards
SAPIEN bioprosthesis may prevent the occurrence of mod-
erate and severe ARs.
Impact of ‘‘Oversizing’’ the Edwards SAPIEN
Bioprosthesis on Aortic Regurgitation
The key finding of this study is that the use of a simple
‘‘oversizing’’ policy was associated with no occurrence of
moderate or severe ARs at 1 month with no case of rupture
of the aortic annulus and no prosthesis–patient mismatch.
This benefit was the result of 3 simple measures, including
(1) exclusion of all patients with an aortic annulus greater
than 24 mm by TEE during the screening process, (2) use
of a 26-mm prosthesis in all patients with aortic annulus
greater than 21, and (3) use of a 26-mm prosthesis in pa-
tients with an aortic annulus 21 or less whenever sizing
based on balloon valvuloplasty with a 23-mm balloon and
contrast angiography suggested that it was feasible.
Our results are consistent with a recent retrospective
analysis of determinants of AR after Edwards SAPIEN bio-
prosthesis implantation by Detaint and colleagues.3 They
observed that oversizing the prosthesis, as estimated by
the ‘‘prosthesis/annulus cover index,’’ was the major factor
associated with the absence of severe AR after implanta-
tion. Of note, in our population the cover index was twice
as high as in the population studied by Detaint and col-
leagues (12.4  4.3 vs 6.7  4). Detaint and colleagues
also found that a moderate to severe AR was never observed
in patients with a ‘‘cover index’’ greater than 8 or an aortic
annulus less than 22 mm. Of note, this combination was
present in 20 of 22 patients (91%) in our population but
in only half of the population studied by Detaint and
colleagues.3
Analysis of the respective role of the criteria used in the
selection process demonstrates that the exclusion of patients
with an annulus greater than 24 mm would have already re-
sulted in a high cover index of 9.9% 3.6%. The use of the
2 additional criteria further increased the cover index of our
population to 12.4%  4.3%.
The exclusion of patients with an aortic annulus greater
than 24 mm is already recommended as a common practice.
However, this rule is not strictly applied, and in a recently
published series, Detaint and colleagues3 reported that an
Edwards SAPIEN was implanted in patients with an annu-
lus greater than 24 mm in more than one third of the cases.ery c February 2013
FIGURE 2. A, Changes in aortic regurgitation in the 18 patients with echocardiography follow-up (P ¼ .03 by 1-way repeated-measures Friedman test).
B, Individual changes in aortic regurgitation from pretreatment to postdischarge. AR, Aortic regurgitation.
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performed at the time of the intervention in a patient in
whom no TEE was performed during the screening process
or there is no other option in this patient. In this context, our
observation that 6 of 28 patients (21%) were finally ex-
cluded on the basis of the TEE, whereas they were initially
considered good candidates for the procedure based on
TTE, advocates the systematic use of TEE as part of the
screening process. This also strengthens the need for larger
endoprostheses. The recent availability of the 29-mm Ed-
wards SAPIEN endoprosthesis will allow this technology
to be offered to patients with an aortic annulus greater
than 24 mm without decreasing the ‘‘cover index’’ and tak-
ing the risk to induce a moderate or severe AR.
In addition, this approach was not associated with any
stent deformation or prosthesis–patient mismatch as shown
by the low transvalvular gradient (8  3 mm Hg). ThisThe Journal of Thoracic and Caobservation combined with the absence of aortic rupture in
our series suggests that despite the presence of calcification,
the aortic annulus keeps some of its ability to be stretched.
Our study also suggests that it might be important to
switch from the TF to the TA approach in case an appropri-
ately sized endoprosthesis cannot be delivered. Because the
new device generation has been downsized, switching to the
TA approach to accommodate the 26-mm bioprosthesis will
be less frequent. This decision will remain critical in pa-
tients with an annulus diameter of approximately 24 mm
in whom the choice to implant a 29-mm bioprosthesis
will imply the switch from the TF to the TA approach.
In our study, the increment of the intended size of the bio-
prosthesis after predilation combined with aortic angiogra-
phy in 3 patients strengthens the importance of this step as
the final critical step to size the annulus and to choose the
appropriate diameter of the bioprosthesis.rdiovascular Surgery c Volume 145, Number 2 403
TABLE 4. Procedural approach for each patient and impact on aortic regurgitation
Gender
Annulus diameter (mm)
Femoral
approach
possible
Approach
used for
delivery
AR during balloon
inflation with a
23–mm balloon
Edwards SAPIEN*
diameter (mm)
AR before
treatment AR at 1 moTTE TEE
Female 19.9 20.6 Yes TF No 23 Mild None/trivial
Maley 21.5 21.9 22F only TA No 26 None/trivial None/trivial
Femaley 22.9 23.5 22F only TA Yes 26 None/trivial None/trivial
Female 22.8 23.5 Yes TF Yes 26 None/trivial Mild
Female 19.8 20.3 No TA No 23 None/trivial NA
Male 22.9 23.5 Yes TF Yes 26 None/trivial Mild
Male 23.5 23.8 No TA Yes 26 None/trivial Mild
Femaley 20.2 20.8 Yes TF Yes 26 Mild None/trivial
Male 20.5 20.8 No TA No 23 None/trivial Mild
Male 22.5 22.9 No TA No 26 None/trivial None/trivial
Maley 20.1 20.7 Yes TF Yes 26 Moderate None/trivial
Male 22.8 23.6 Yes TF Yes 26 Moderate None/trivial
Female 20.4 21.0 22F only TF No 23 Mild NA
Femaley 20.9 21.4 22F only TA No 26 Severe None/trivial
Femaley 20.2 20.6 No TA Yes 26 Moderate None/trivial
Male 23.2 23.7 No TA Yes 26 None/trivial None/trivial
Female 19.0 19.9 No TA No 23 None/trivial None/trivial
Male 21.9 22.5 No TA No 26 None/trivial NA
Male 22.7 23.2 No TA No 26 Mild NA
Female 20.3 20.9 22F only TF No 23 Mild None/trivial
Male 23.0 23.4 Yes TF Yes 26 None/trivial Mild
Female 21.7 22.9 Yes TF No 26 None/trivial None/trivial
TTE, Transthoracic echocardiography; TEE, transesophageal echocardiography; AR, aortic regurgitation; TF, transfemoral; TA, transapical; NA, not available. *Edwards
Lifesciences LLC, Irvine Calif. yPatients in whom the procedure was modified.
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DAlthough the strategy applied in our population was asso-
ciated with no occurrence of moderate to severe AR, it did
not prevent the occurrence of mild AR in 5 of 11 patients
without AR at pretreatment. Further improvements in bio-
prosthesis design or implantation strategy are still needed
to avoid this complication.
In this series, no event associatedwith the oversizing strat-
egywas observed. In particular, no case of annulus rupture or
stroke was observed. The rates of myocardial infarction
(4%) and heart block requiring pacemaker (4%) are on par
with those described in previous series and in the recently
published PARTNER trial.16 Fluoroscopy and TEE per-
formed at the end of the procedure did not show distortion
of the struts of the stent. Likewise, TTE performed before
discharge or at 1-month follow-up did not show high trans-
valvular gradient suggestive of prosthesis–patientmismatch.
Of note, in this series, a benefit on LV dimensions was ob-
served as early as 1 month after the procedure. Although it
takes several months to achieve near complete LV remodel-
ing after conventional aortic surgery for aortic stenosis,17 se-
ries including early echocardiography follow-up after aortic
replacement for aortic stenosis or aortic regurgitation demon-
strated changes in LV dimensionswithin days of surgery.18,19
The results of our series in which no case of moderate to
severe aortic regurgitation was observed postprocedure are
consistent with those previous observations. In addition, the404 The Journal of Thoracic and Cardiovascular Surgdisappearance of moderate to severe aortic regurgitation
that was present at pretreatment in approximately 25% of
our patient population may have played a role.
Study Limitations
This was a single-center study, and patient referral
and medical management may have influenced the re-
sults. However, the prospectively designed nature of
our policy of ‘‘oversizing’’ the implantation of the Ed-
wards SAPIEN bioprosthesis, the consecutive nature of
the population, and the individual patient analysis of
the serial echocardiography follow-up provide useful in-
sights into the benefit of TAVI with the Edwards SA-
PIEN valve on aortic regurgitation. The lack of
information on wall thickness and myocardial mass
and the lack of a longer echocardiography follow-up
may limit the interpretation of the benefit of the strategy
on LV remodeling. Finally, although no event related to
the oversizing strategy was observed, we must acknowl-
edge that the number of patients included in the present
study is too small to draw a definite conclusion on the
safety of this approach.
CONCLUSIONS
On the basis of an individual and serial patient analysis,
the present report provides important information on theery c February 2013
Samim et al Acquired Cardiovascular Disease
A
C
Doutcome of AR after implantation of an Edwards SAPIEN
valve in the aortic position. In particular, the results suggest
that a simple ‘‘oversizing’’ policy may prevent the occur-
rence of moderate and severe ARs. Although these findings
need confirmation in studies including more patients and
with a longer follow-up, they support the use of larger endo-
prostheses (29 mm) to adequately treat patients with an an-
nulus greater than 24 mm.
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